Page 121 - 2021年14期

2018，38（4）：639-654. set of effect and impact on health-related quality of life，
[ 8 ] TAN L D，BRATT J M，GODOR D，et al. Benralizumab：a exacerbation rate，lung function，and nasal polyposis
unique IL-5 inhibitor for severe asthma[J]. J Asthma symptoms for patients with severe eosinophilic asthma
Allergy，2016，9（4）：71-81. treated with benralizumab（ANDHI）：a randomised，con-
[ 9 ] LAVIOLETTE M，GOSSAGE D L，GAUVREAU G，et al. trolled，phase 3b trial[J]. Lancet Respir Med，2021，9（3）：
Effects of benralizumab on airway eosinophils in asthma- 260-274.
tic patients with sputum eosinophilia[J]. J Allergy Clin [19] CHUNG K F，WENZEL S E，BROZEK J L，et al. Interna-
Immunol，2013，132（5）：1086-1096. tional ERS/ATS guidelines on definition，evaluation and
[10] CASTRO M，WENZEL S E，BLEECKER E R，et al. Ben- treatment of severe asthma[J]. Eur Respir J，2014，43（2）：
ralizumab，an anti-interleukin 5 receptor α monoclonal an- 343-373.
tibody，versus placebo for uncontrolled eosinophilic asth- [20] HAYASHINO Y，NOGUCHI Y，FUKUI T. Systematic
ma：a phase 2b randomised dose-ranging study[J]. Lancet evaluation and comparison of statistical tests for publica-
Respir Med，2014，2（11）：879-890. tion bias[J]. J Epidemiol，2005，15（6）：235-243.
[11] NOWAK R M，PARKER J M，SILVERMAN R A，et al. [21] KASSA G M. Mother-to-child transmission of HIV infec-
Arandomized trial of benralizumab，an antiinterleukin 5 tion and its associated factors in Ethiopia：a systematic re-
receptor α monoclonal antibody，after acute asthma[J]. view and meta-analysis[J]. BMC Infect Dis，2018，18（1）：
Am J Emerg Med，2015，33（1）：14-20. 1-9.
[22] 王吉耀.循证医学与临床实践[M]. 4 版.北京：科学出版
[12] PARK H S，KIM M K，IMAI N，et al. A phase 2a study of
社，2019：122.
benralizumab for patients with eosinophilic asthma in
[23] WANG B，YAN L，HUTMACHER M，et al. Exposure-re-
South Korea and Japan[J]. Int Arch Allergy Immunol，
sponse analysis for determination of benralizumab optimal
2016，169（3）：135-45.
dosing regimen in adults with asthma[J]. Am J Respir Crit
[13] FITZGERALD J M，BLEECKER E R，NAIR P，et al. Ben-
Care Med，2014，189（9）：A1324.
ralizumab，an anti-interleukin-5 receptor α monoclonal an-
[24] PAPI A，BLASI F，CANONICA G W，et al. Treatment
tibody，as add-on treatment for patients with severe，un-
strategies for asthma：reshaping the concept of asthma
controlled，eosinophilic asthma （CALIMA） ：a ran-
management[J]. Allergy Asthma ClinImmunol，2020，16
domised，double-blind，placebo-controlled phase 3 trial[J].
（3）：75-85.
Lancet，2016，388（10056）：2128-2141.
[25] KITCH B T，PALTIEL A D，KUNTZ K M，et al. A single
[14] BLEECKER E R，FITZGERALD J M，CHANEZ P，et al.
measure of FEV1 is associated with risk of asthma attacks
Efficacy and safety of benralizumab for patients with se-
in long-term follow-up[J]. Chest，2004，126（6）：1875-
vere asthma uncontrolled with high-dosage inhaled corti-
1882.
costeroids and long-acting β 2-agonists（SIROCCO）：a ran-
[26] JUNIPER E F，SVENSSON K，MORK A C，et al. Mea-
domised，multicentre，placebo-controlled phase 3 trial[J].
surement properties and interpretation of three shortened
Lancet，2016，388（10056）：2115-2127.
versions of the asthma control questionnaire[J]. Respir
[15] NAIR P，WENZEL S，RABE K F，et al. Oral glucocorti-
Med，2005，99（5）：553-558.
coid-sparing effect of benralizumab in severe asthma[J].
[27] 齐军，吴倩，李森，等.哮喘控制问卷与哮喘生命质量问卷
N Engl J Med，2017，376（25）：2448-2458.
在哮喘患者中的应用价值研究[J].国际呼吸杂志，2014，
[16] FERGUSON G T，FITZGERALD J M，BLEECKER E R， 34（3）：174-176.
et al. Benralizumab for patients with mild to moderate，
[28] TIAN B P，ZHANG G S，LOU J，et al. Efficacy and safety
persistent asthma（BISE）：a randomised，double-blind，pla- of benralizumab for eosinophilic asthma：a systematic re-
cebo-controlled，phase 3 trial[J]. Lancet Respir Med， view and meta-analysis of randomized controlled trials[J].
2017，5（7）：568-576. J Asthma，2018，55（9）：956-965.
[17] PANETTIERI R A，Jr，WELTE T，SHENOY K V，et al. [29] BUSSE W W，BLEECKER E R，FITZGERALD J M，et al.
Onset of effect，changes in airflow obstruction and lung Long-term safety and efficacy of benralizumab in patients
volume，and health-related quality of life improvements with severe，uncontrolled asthma：1-year results from the
with benralizumab for patients with severe eosinophilic BORA phase 3 extension trial[J]. Lancet Respir Med，
asthma：phase Ⅲb randomized，controlled trial（SOLANA） 2019，7（1）：46-59.
[J]. J Asthma Allergy，2020，13（2）：115-126. （收稿日期：2021-02-01 修回日期：2021-05-15）
[18] HARRISON T W，CHANEZ P，MENZELLA F，et al. On- （编辑：林 静）

中国药房 2021年第32卷第14期 China Pharmacy 2021 Vol. 32 No. 14 ·1775 ·